FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034306276> ?p ?o ?g. }

• W2034306276 endingPage "1586" @default.
• W2034306276 startingPage "1581" @default.
• W2034306276 abstract "Increased frequency of hyperfibrinolytic activity was reported in patients with cirrhosis. However, the incidence, clinical presentation, and the parameters related to hyperfibrinolysis remain largely unknown in these patients. By utilizing euglobulin lysis time (ELT) and other clinical coagulation tests, the present study investigated the incidence of and clinical parameters related to hyperfibrinolytic activity, and assessed predicting factors to epsilon-aminocaproic acid (EACA) treatment in cirrhotic patients with hyperfibrinolysis in a liver unit.The study included 86 consecutive patients who were referred and admitted to a referral liver unit for various liver diseases. The mean age was 50.0 yr, with a male: female ratio of 60:26. Sixty-six patients (76.7%) were Hispanic and 75 (87.2%) were cirrhotic. The etiologies of liver diseases included alcoholic liver disease (n = 68, 79.1%), hepatitis B (n = 2, 2.3%), hepatitis C (n = 6, 7.0%), autoimmune hepatitis (n = 3, 3.5%), cryptogenic liver disease (n = 4, 4.7%), and hepatocellular carcinoma (n = 3, 3.5%). Coagulation studies included ELT, PT, PTT, fibrinogen, D-dimer, and fibrin degradation product levels.Hyperfibrinolytic activity as reflected by shortened ELT was present in 27/75 cirrhotic (31.3%) but 0/11 noncirrhotic patients, which was significantly correlated with higher Child-Pugh (C-P) class, abnormal levels of PT, PTT, fibrinogen, platelet count, and total bilirubin. Shortened ELT was more frequently seen in patients with hepatic decompensation and mucocutaneous bleeding, although these relationships were not statistically significant. In 27 patients with hyperfibrinolysis, five (18.5%) required EACA treatment for progressive mucocutaneous bleeding and/or hematoma. EACA treatment was significantly associated with higher C-P scores; greatly shortened ELT (< or =50% of normal value); and abnormal levels of fibrinogen, total bilirubin, and PT, indicating that these factors may serve as predictors for EACA treatment.Hyperfibrinolytic activity was seen in 31.3% of patients with cirrhosis, which is correlated with higher C-P scores; abnormal PT, PTT, fibrinogen level, and platelet count; and hyperbilirubinemia. Patients who received EACA treatment usually have a more severe hyperfibrinolytic activity as indicated by shortened ELT and low level of fibrinogen, and more severe liver disease as indicated by higher C-P scores and hyperbilirubinemia." @default.
• W2034306276 created "2016-06-24" @default.
• W2034306276 creator A5027202463 @default.
• W2034306276 creator A5047602581 @default.
• W2034306276 creator A5049360238 @default.
• W2034306276 creator A5053853521 @default.
• W2034306276 creator A5070400043 @default.
• W2034306276 date "2001-05-01" @default.
• W2034306276 modified "2023-10-18" @default.
• W2034306276 title "Hyperfibrinolytic Activity in Hospitalized Cirrhotic Patients in a Referral Liver Unit" @default.
• W2034306276 cites W1769450009 @default.
• W2034306276 cites W1972685036 @default.
• W2034306276 cites W1978794823 @default.
• W2034306276 cites W1985568976 @default.
• W2034306276 cites W1991965485 @default.
• W2034306276 cites W2001469783 @default.
• W2034306276 cites W2010009697 @default.
• W2034306276 cites W2063957255 @default.
• W2034306276 cites W2065459298 @default.
• W2034306276 cites W2066175802 @default.
• W2034306276 cites W2091742879 @default.
• W2034306276 cites W2125320734 @default.
• W2034306276 cites W2160390803 @default.
• W2034306276 cites W2167695527 @default.
• W2034306276 cites W2167722196 @default.
• W2034306276 cites W2170708773 @default.
• W2034306276 cites W2330819872 @default.
• W2034306276 cites W2440988955 @default.
• W2034306276 cites W4243837652 @default.
• W2034306276 cites W4297907675 @default.
• W2034306276 cites W76744835 @default.
• W2034306276 doi "https://doi.org/10.1111/j.1572-0241.2001.03781.x" @default.
• W2034306276 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11374703" @default.
• W2034306276 hasPublicationYear "2001" @default.
• W2034306276 type Work @default.
• W2034306276 sameAs 2034306276 @default.
• W2034306276 citedByCount "86" @default.
• W2034306276 countsByYear W20343062762012 @default.
• W2034306276 countsByYear W20343062762013 @default.
• W2034306276 countsByYear W20343062762014 @default.
• W2034306276 countsByYear W20343062762015 @default.
• W2034306276 countsByYear W20343062762016 @default.
• W2034306276 countsByYear W20343062762017 @default.
• W2034306276 countsByYear W20343062762018 @default.
• W2034306276 countsByYear W20343062762019 @default.
• W2034306276 countsByYear W20343062762020 @default.
• W2034306276 countsByYear W20343062762021 @default.
• W2034306276 countsByYear W20343062762022 @default.
• W2034306276 countsByYear W20343062762023 @default.
• W2034306276 crossrefType "journal-article" @default.
• W2034306276 hasAuthorship W2034306276A5027202463 @default.
• W2034306276 hasAuthorship W2034306276A5047602581 @default.
• W2034306276 hasAuthorship W2034306276A5049360238 @default.
• W2034306276 hasAuthorship W2034306276A5053853521 @default.
• W2034306276 hasAuthorship W2034306276A5070400043 @default.
• W2034306276 hasConcept C120665830 @default.
• W2034306276 hasConcept C121332964 @default.
• W2034306276 hasConcept C126322002 @default.
• W2034306276 hasConcept C2776029263 @default.
• W2034306276 hasConcept C2777075537 @default.
• W2034306276 hasConcept C2777214474 @default.
• W2034306276 hasConcept C2778019345 @default.
• W2034306276 hasConcept C2779036427 @default.
• W2034306276 hasConcept C2780434524 @default.
• W2034306276 hasConcept C2781219028 @default.
• W2034306276 hasConcept C61511704 @default.
• W2034306276 hasConcept C71924100 @default.
• W2034306276 hasConcept C90924648 @default.
• W2034306276 hasConceptScore W2034306276C120665830 @default.
• W2034306276 hasConceptScore W2034306276C121332964 @default.
• W2034306276 hasConceptScore W2034306276C126322002 @default.
• W2034306276 hasConceptScore W2034306276C2776029263 @default.
• W2034306276 hasConceptScore W2034306276C2777075537 @default.
• W2034306276 hasConceptScore W2034306276C2777214474 @default.
• W2034306276 hasConceptScore W2034306276C2778019345 @default.
• W2034306276 hasConceptScore W2034306276C2779036427 @default.
• W2034306276 hasConceptScore W2034306276C2780434524 @default.
• W2034306276 hasConceptScore W2034306276C2781219028 @default.
• W2034306276 hasConceptScore W2034306276C61511704 @default.
• W2034306276 hasConceptScore W2034306276C71924100 @default.
• W2034306276 hasConceptScore W2034306276C90924648 @default.
• W2034306276 hasIssue "5" @default.
• W2034306276 hasLocation W20343062761 @default.
• W2034306276 hasLocation W20343062762 @default.
• W2034306276 hasOpenAccess W2034306276 @default.
• W2034306276 hasPrimaryLocation W20343062761 @default.
• W2034306276 hasRelatedWork W2255318257 @default.
• W2034306276 hasRelatedWork W2285110614 @default.
• W2034306276 hasRelatedWork W2349929856 @default.
• W2034306276 hasRelatedWork W2367164280 @default.
• W2034306276 hasRelatedWork W2376162169 @default.
• W2034306276 hasRelatedWork W2412677110 @default.
• W2034306276 hasRelatedWork W2530203677 @default.
• W2034306276 hasRelatedWork W2753450992 @default.
• W2034306276 hasRelatedWork W3197598734 @default.
• W2034306276 hasRelatedWork W4210912349 @default.
• W2034306276 hasVolume "96" @default.
• W2034306276 isParatext "false" @default.

• next